Compositions and methods for improved detection and classification of neoplasms

• US 6,623,936 B1
• Filed: 02/07/2000
• Issued: 09/23/2003
• Est. Priority Date: 09/24/1999
• Status: Expired due to Fees

• Current Assignee: Imgenex Corp. (Bio-Techne Corporation)
• Original Assignee: Imgenex Corp. (Bio-Techne Corporation)
• Inventors: Singh, Sujay, Dias, Peter
• Primary Examiner(s): Ungar, Susan
• Assistant Examiner(s): DAVIS, MINH TAM B
• Application Number:
  US09/499,559
• Time in Patent Office: 1,324 Days
• Field of Search: 435/6, 435/7.1, 435/7.23, 435/7.9, 435/7.91, 435/7.92, 435/7.93, 435/7.94, 435/7.95, 530/350, 530/387.1
• US Class Current: 435/7.2
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: G01N 2333/4706 stimulating, promoting or activating activity
• CPC Class Codes: G01N 2333/475 Assays involving growth factors
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/574 for cancer

Abstract

A method for diagnosing clinically distinct embryonal and alveolar subtypes of rhabdomyosarcoma, including contacting a reagent including an antibody that specifically binds myogenin with a sample that includes at least one rhabdomyosarcoma cell or at least one extract of at least one rhabdomyosarcoma cell, detecting the binding of the antibody to the sample to determine the presence, absence, or amount of myogenin in the sample, and diagnosing clinically distinct embryonal and alveolar subtypes of rhabdomyosarcoma, alveolar rhabdomyosarcoma having an increased amount of binding as compared to embryonal rhabdomyosarcoma.

Claims

1. A method for diagnosing clinically distinct embryonal and alveolar subtypes of rhabdomyosarcoma, comprising:

a) contacting a reagent comprising an antibody that specifically binds myogenin with a sample that comprises at least one rhabdomyosarcoma cell or at least one extract of an rhabdomyosarcoma cell;

b) detecting the binding of said antibody to said sample to determine the presence, absence, or amount of myogenin in said sample; and

c) diagnosing clinically distinct embryonal and alveolar subtypes of rhabdomysarcoma, wherein alveolar rhabdomyosarcoma has an increased amount of binding as compared to embryonal rhabdomyosarcoma.

2. The method of claim 1, wherein said sample comprises at least one rhabdomyosarcoma cell.

3. The method of claim 1, wherein said sample comprises an extract of at least one rhabdomyosarcoma cell.

4. The method of claim 1, wherein said antibody is detectably labeled.

5. The method of claim 1, wherein said detecting uses a detectably labeled antibody that binds to said antibody that specifically binds to myogenin.